Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

How DXS International (AQSE:DXSP) Returned to a Small After-Tax Profit as Revenue Dipped

DXS International is quoted on the Aquis Stock Exchange Growth Market under the code DXSP. The company describes itself as a digital clinical decision support business, providing treatment guidelines and guidance to healthcare professionals during patient consultations. Its products include SMART Referral software and …

Divya Sood | 05 October 2026

Moderna (NASDAQ:MRNA) Stock: Why a Nasdaq-100 Promotion Drew Index Buyers

Moderna (NASDAQ:MRNA) shares rallied on Friday after the biotechnology company was flagged to join the Nasdaq-100 index. The inclusion is set to take effect before the open on 9 October 2026, and the prospect of that change was the confirmed catalyst for the move. …

Nitish Kishor | 05 October 2026

Vogenx (NASDAQ:VOGX) Plunges as Chipmakers Power the Market Higher

● No clinical-trial result, regulatory decision, financing disclosure,Partnershipannouncement or analyst rating change could be reliably dated to the session.

Nitish Kishor | 05 October 2026

Voyager Therapeutics (NASDAQ:VYGR) Falls as Gene Therapy Stock Trades on Its Own

● Voyager Therapeutics closed at $2.45 on Friday, October 2, 2026, a decline of 8.41% on the session.

Nitish Kishor | 05 October 2026

TELA Bio (NASDAQ:TELA) Retreats as Medical Device Stock Lags the Market

● No press release, regulatory update, clinical disclosure or corporate announcement tied to the session could be confirmed from available sources.

Nitish Kishor | 05 October 2026

MediciNova (NASDAQ:MNOV) Rises as Drug Developer Draws Speculative Buying

● No clinical-trial result, regulatory decision, financing or analyst action could be tied to the session to explain the move.

Nitish Kishor | 05 October 2026

Nautilus Biotechnology (NASDAQ:NAUT) Rockets as Biotech Buyers Pile In

● No clinical readout, regulatory decision, partnership, financing orEarningsevent was identified for October 2 to account for the gain.

Nitish Kishor | 05 October 2026

Myriad Genetics (NASDAQ:MYGN) Gains Ground as Investors Return to Diagnostics Names

● NoEarningsrelease, test launch, reimbursement decision or analyst action could be tied to the session.

Nitish Kishor | 05 October 2026

Nanobiotix (NASDAQ:NBTX) Slips While Major Indexes Advance

● No clinical-trial result, regulatory decision, licensing orPartnershipannouncement, management change or analyst action could be dated to the session.

Nitish Kishor | 05 October 2026

Anbio Biotechnology (NASDAQ:NNNN) Slips Despite a Rising Market

● Anbio Biotechnology closed at $5.55 on Friday, October 2, 2026, a decline of 11.77% on the session.

Nitish Kishor | 05 October 2026
Support

Hi! How can we help you today?

Loading…